Patents by Inventor Lincoln Krochmal

Lincoln Krochmal has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
    Publication number: 20200190521
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: September 20, 2019
    Publication date: June 18, 2020
    Applicant: Excaliard Pharmaceuticals, Inc.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
    Publication number: 20170022501
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: September 25, 2015
    Publication date: January 26, 2017
    Applicant: EXCALIARD PHARMACEUTICALS, INC.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
    Patent number: 9173894
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: November 3, 2015
    Assignee: Excaliard Pharamaceuticals, Inc.
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • METHOD OF TREATING KELOIDS OR HYPERTROPHIC SCARS USING ANTISENSE COMPOUNDS TARGETING CONNECTIVE TISSUE GROWTH FACTOR (CTGF)
    Publication number: 20120238937
    Abstract: This invention provides methods of preventing formation of, or treating, fibrotic lesions, including skin scars such as keloids and hypertrophic scars which comprise administering to the subject by one or more injection a compound which comprises a modified oligonucleotide, such as a modified antisense oligonucleotide, siRNA, or oligodeoxyribonucleotide, which inhibits expression of protein involved in fibrosis. Dosing of the antisense using an intradermal threading technique is also described.
    Type: Application
    Filed: February 2, 2012
    Publication date: September 20, 2012
    Inventors: Nicholas M. Dean, Lincoln Krochmal, Gregory Hardee, J. Gordon Foulkes, Niall O'Donnell, Leroy Young, Mark Jewell
  • Acne gel
    Publication number: 20060222712
    Abstract: This combination of clindamycin (1%) and tretinoin (0.025%), solubilized in a hydrogel, resulted in significantly greater improvements in acne vulgaris (reduced lesion counts and ISGA) than either drug alone or vehicle and effectively treated both non-inflammatory and inflammatory lesions with a convenient, once-daily application.
    Type: Application
    Filed: February 17, 2006
    Publication date: October 5, 2006
    Applicant: Connetics Corporation
    Inventors: Lincoln Krochmal, Alex Yaroshinsky